Edgestream Partners’s NovoCure NVCR Stock Holding History

Edgestream Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Buy	+19,859	New	+$300K	0.01%	864
2025 Q3	–	Sell	-208,329	Closed	-$3.71M	–	1002
2025 Q2	$3.71M	Buy	208,329 +48,057	+30%	+$837K	0.1%	375
2025 Q1	$2.86M	Buy	+160,272	New	+$3.64M	0.1%	388
2024 Q4	–	Sell	-115,929	Closed	-$1.81M	–	1020
2024 Q3	$1.81M	Buy	+115,929	New	+$2.1M	0.08%	433
2024 Q1	–	Sell	-105,899	Closed	-$1.58M	–	963
2023 Q4	$1.58M	Buy	+105,899	New	+$1.42M	0.11%	300
2023 Q1	–	Sell	-34,635	Closed	-$2.54M	–	622
2022 Q4	$2.54M	Buy	34,635 +20,477	+145%	+$1.54M	0.29%	103
2022 Q3	$1.08M	Buy	+14,158	New	+$1.1M	0.08%	267

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Edgestream Partners's NVCR Position: Q2 2026 in Review

Edgestream Partners opened a new position in NovoCure (NVCR) in Q2 2026: 19,859 shares worth $301K. The stake represents 0.01% of the portfolio and ranks #864 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in NVCR as recently as Q2 2025.

Edgestream Partners first reported a position in NVCR in Q3 2022 and has held it in 7 quarters since. The position peaked at $3.71M in Q2 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Edgestream Partners held 19,859 shares of NovoCure worth $301K as of Q2 2026.
NovoCure was a new Edgestream Partners position in Q2 2026.
NovoCure made up 0.01% of Edgestream Partners's portfolio in Q2 2026, its #864 holding.
Edgestream Partners first reported a position in NovoCure in Q3 2022 and has held it in 7 quarters since.
Edgestream Partners's NovoCure position peaked at $3.71M in Q2 2025.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.